Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.
De Vincentis A, D'Amato D, Cristoferi L, Gerussi A, Malinverno F, Lleo A, Colapietro F, Marra F, Galli A, Fiorini C, Coco B, Brunetto M, Niro GA, Cotugno R, Saitta C, Cozzolongo R, Losito F, Giannini EG, Labanca S, Marzioni M, Marconi G, Morgando A, Pellicano R, Vanni E, Cazzagon N, Floreani A, Chessa L, Morelli O, Muratori L, Pellicelli A, Pompili M, Ponziani F, Tortora A, Rosina F, Russello M, Cannavò M, Simone L, Storato S, Viganò M, Abenavoli L, D'Antò M, De Gasperi E, Distefano M, Scifo G, Zolfino T, Calvaruso V, Cuccorese G, Palitti VP, Sacco R, Bertino G, Frazzetto E, Alvaro D, Mulinacci G, Palermo A, Scaravaglio M, Terracciani F, Galati G, Ronca V, Zuin M, Claar E, Izzi A, Picardi A, Invernizzi P, Vespasiani-Gentilucci U, Carbone M; on behalf of the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group and, the Italian PBC Registry. De Vincentis A, et al. Among authors: zolfino t. Liver Int. 2022 Nov;42(11):2453-2465. doi: 10.1111/liv.15386. Epub 2022 Aug 23. Liver Int. 2022. PMID: 35932095 Free PMC article.
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Petta S, et al. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28497758
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Ascione A, et al. Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28. Infection. 2018. PMID: 29808463
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study.
Sacco R, Granito A, Bargellini I, Zolfino T, Saitta C, Marzi L, Tapete G, Bresci G, Marinelli S, Tovoli F, Attardo S, Rossi M, Urbani L, Marchi S, Buccianti P, Cabibbo G. Sacco R, et al. Among authors: zolfino t. Future Oncol. 2018 Dec;14(29):3049-3058. doi: 10.2217/fon-2018-0281. Epub 2018 Aug 9. Future Oncol. 2018. PMID: 30091371
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
Vespasiani-Gentilucci U, Rosina F, Pace-Palitti V, Sacco R, Pellicelli A, Chessa L, De Vincentis A, Barlattani M, Barlattani A, Feletti V, Mussetto A, Zolfino T, Russello M, Cozzolongo R, Garrucciu G, Niro G, Bacca D, Bertino G, Claar E, Ascione A, D'Adamo G, Adinolfi LE, Scifo G, Izzi A; CLEO-AIGO PBC study group. Vespasiani-Gentilucci U, et al. Among authors: zolfino t. Scand J Gastroenterol. 2019 Oct;54(10):1274-1282. doi: 10.1080/00365521.2019.1669702. Epub 2019 Sep 28. Scand J Gastroenterol. 2019. PMID: 31564176
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy].
D'Angelo S, Germano D, Zolfino T, Sansonno D, Giannitrapani L, Benedetti A, Montesarchio V, Attili A, Buonadonna A, Barni S, Gasbarrini A, Burlone ME, Cillo U, Marenco S, Villa E, Giovanis P, Proserpio I, Saitta C, Magini G, Cengarle R, Fava G, Cuttone F, Calvani N, Angelico M, Di Costanzo F, Noto A, Poggi G, Marignani M, Cascinu S, Amoroso D, Palmieri V, Massa E, Crocè LS, Picardi A, Tumulo S, Erminero C, Lencioni R, Lorusso V. D'Angelo S, et al. Among authors: zolfino t. Recenti Prog Med. 2015 May;106(5):217-26. doi: 10.1701/1868.20406. Recenti Prog Med. 2015. PMID: 25994538 Italian.
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis.
Littera R, Chessa L, Onali S, Figorilli F, Lai S, Secci L, La Nasa G, Caocci G, Arras M, Melis M, Cappellini S, Balestrieri C, Serra G, Conti M, Zolfino T, Casale M, Casu S, Pasetto MC, Barca L, Salustro C, Matta L, Scioscia R, Zamboni F, Faa G, Orrù S, Carcassi C. Littera R, et al. Among authors: zolfino t. PLoS One. 2016 Jan 8;11(1):e0146086. doi: 10.1371/journal.pone.0146086. eCollection 2016. PLoS One. 2016. PMID: 26744892 Free PMC article.
12 results